A phase 1/2 clinical trial showed that low-dose oral NMN (450mg twice daily for 2 weeks) was safe and well-tolerated in 25 patients with steroid-resistant immune thrombocytopenia (ITP), with no serious adverse events. The study found that 20% of patients achieved the primary endpoint of platelet recovery, while 60% showed meaningful platelet count improvements. The mechanism involves NMN restoring NAD+ levels, which reprograms immune macrophages to reduce their destruction of platelets while preserving normal immune function.
For your business
Recent human trial data shows NMN at 900mg daily safely improved platelet counts in autoimmune patients without compromising immune function.